Novo Nordisk, the Danish pharmaceutical giant, has experienced a significant price dip, falling over 40% from its all-time highs in June 2024. This decline stems from several challenges, including the entrance of competitors offering weight-loss drugs, less successful clinical trial results than anticipated, and heightened uncertainty due to new U.S. political administration policies and potential tariffs on foreign pharmaceutical companies.